Amneal Pharmaceuticals, Inc.

As of March 1, 2024, Amneal Pharmaceuticals, Inc. is considered a risky investment due to its high P/E ratio of 58, negative price-to-book value, and premium EV to EBITDA ratio, despite recent strong stock performance and long-term returns that may not justify its current valuation.

As of March 1, 2024, Amneal Pharmaceuticals is considered overvalued with a high P/E ratio of 58, a negative price to book value of -17.93, and a return of 19.02% over the past year, which is lower than the S&P 500's 10.26% return, indicating a shift from fair to risky valuation.

As of June 6, 2025, the market trend is mildly bearish with mixed signals, as weekly indicators show bullish momentum while monthly indicators lean bearish, suggesting caution in trading decisions.

As of March 2022, the management team of Amneal Pharmaceuticals, Inc. includes Independent Chairman Paul Meister, Co-CEOs Chirag and Chintu Patel, and several independent directors, including Gautam Patel, Emily Alva, J. Kevin Buchi, Jeffrey George, and John Kiely. This team is responsible for guiding the company's strategic direction.

Amneal Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and markets generic and branded pharmaceutical products. As of March 2025, it reported net sales of $695 million and a net profit of $25 million, with a market cap of approximately $2.45 billion.

As of Jun 18, Amneal Pharmaceuticals, Inc. has a market capitalization of $2.45 billion, with net sales of $2.83 billion and a net profit of $32.43 million over the latest four quarters.